Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:LNTHNASDAQ:OCDXNASDAQ:QDEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$19.57-0.1%$19.27$14.40▼$47.00$1.30B1.59881,217 shs377,561 shsLNTHLantheus$101.77-1.8%$97.37$63.76▼$126.89$6.97B0.2952,288 shs644,509 shsOCDXOrtho Clinical Diagnostics$17.63$17.63$16.04▼$22.99$3.92B1.321.24 million shs5,400 shsQDELQuidelOrtho$28.09+1.1%$33.89$23.77▼$49.45$1.89B0.43997,777 shs1.19 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+0.77%+6.99%-2.83%-18.48%-47.11%LNTHLantheus+2.41%+2.29%+3.88%+6.30%+58.93%OCDXOrtho Clinical Diagnostics0.00%0.00%0.00%0.00%0.00%QDELQuidelOrtho+7.52%+10.37%-21.41%-37.21%-31.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics2.7243 of 5 stars4.43.00.00.03.40.00.0LNTHLantheus4.4825 of 5 stars3.52.00.04.23.52.51.9OCDXOrtho Clinical DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/AQDELQuidelOrtho4.2778 of 5 stars3.13.00.03.82.01.72.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.89Moderate Buy$54.33177.64% UpsideLNTHLantheus 3.00Buy$129.4327.18% UpsideOCDXOrtho Clinical Diagnostics 0.00N/AN/AN/AQDELQuidelOrtho 2.29Hold$46.8366.73% UpsideCurrent Analyst Ratings BreakdownLatest OCDX, LNTH, QDEL, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025QDELQuidelOrthoJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$38.00 ➝ $25.003/21/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $122.003/20/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$46.003/3/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$42.00 ➝ $36.002/28/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.002/27/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$120.00 ➝ $127.002/13/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$44.002/13/2025QDELQuidelOrthoRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$64.00 ➝ $61.002/13/2025QDELQuidelOrthoUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$43.00 ➝ $45.001/29/2025CLDXCelldex TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M185.06N/AN/A$9.08 per share2.16LNTHLantheus$1.53B4.54$8.49 per share11.98$11.91 per share8.54OCDXOrtho Clinical Diagnostics$2.04B1.92$2.28 per share7.73$1.99 per share8.86QDELQuidelOrtho$2.78B0.68$21.78 per share1.29$44.75 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$141.43M-$2.45N/AN/AN/A-1,544.32%-19.75%-18.86%5/5/2025 (Estimated)LNTHLantheus$326.66M$4.3716.9316.13N/A28.57%44.29%23.52%5/7/2025 (Estimated)OCDXOrtho Clinical Diagnostics-$54.30M-$0.01N/A17.631.66-0.02%41.71%5.10%N/AQDELQuidelOrtho-$2.03B-$30.28N/A8.75N/A-72.84%3.78%1.80%5/7/2025 (Estimated)Latest OCDX, LNTH, QDEL, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025LNTHLantheus$1.64N/AN/AN/A$377.37 millionN/A5/7/2025Q1 2025QDELQuidelOrtho$0.61N/AN/AN/A$694.97 millionN/A5/5/2025Q1 2025CLDXCelldex Therapeutics-$0.75N/AN/AN/A$1.08 millionN/A2/27/2025Q4 2024CLDXCelldex Therapeutics-$0.73-$0.71+$0.02-$0.71$1.25 million$1.18 million2/27/2025Q4 2024LNTHLantheus$1.57$1.34-$0.23-$0.17$376.61 million$391.11 million2/12/2025Q4 2024QDELQuidelOrtho$1.07$0.63-$0.44-$2.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AOCDXOrtho Clinical DiagnosticsN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A24.2724.27LNTHLantheusN/A1.651.56OCDXOrtho Clinical Diagnostics4.911.891.29QDELQuidelOrtho0.711.220.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/ALNTHLantheus99.06%OCDXOrtho Clinical DiagnosticsN/AQDELQuidelOrtho99.00%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics3.80%LNTHLantheus2.00%OCDXOrtho Clinical DiagnosticsN/AQDELQuidelOrtho1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableLNTHLantheus70068.48 million68.48 millionOptionableOCDXOrtho Clinical Diagnostics4,800222.59 millionN/ANot OptionableQDELQuidelOrtho7,00067.46 million66.58 millionOptionableOCDX, LNTH, QDEL, and CLDX HeadlinesRecent News About These CompaniesT. Rowe Price Investment Management Inc. Has $500.69 Million Holdings in QuidelOrtho Co. (NASDAQ:QDEL)April 25 at 6:34 AM | marketbeat.comWhy QuidelOrtho (QDEL) Could Beat Earnings Estimates AgainApril 24 at 1:15 PM | zacks.comMarshall Wace LLP Raises Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL)April 24 at 4:33 AM | marketbeat.comQuidelOrtho to Report First Quarter 2025 Financial Results | QDEL Stock NewsApril 23 at 4:53 PM | gurufocus.comQuidelOrtho to Report First Quarter 2025 Financial ResultsApril 23 at 4:30 PM | businesswire.comJPMorgan Chase & Co. Cuts QuidelOrtho (NASDAQ:QDEL) Price Target to $25.00April 23 at 1:44 PM | marketbeat.comQuidelOrtho Co. (NASDAQ:QDEL) Shares Bought by Van Lanschot Kempen Investment Management N.V.April 23 at 6:28 AM | marketbeat.comBridgewater Associates LP Reduces Holdings in QuidelOrtho Co. (NASDAQ:QDEL)April 23 at 4:07 AM | marketbeat.comQuidelOrtho Co. (NASDAQ:QDEL) Position Reduced by Bank of Montreal CanApril 23 at 3:40 AM | marketbeat.comJPMorgan Chase & Co. Has Lowered Expectations for QuidelOrtho (NASDAQ:QDEL) Stock PriceApril 23 at 2:47 AM | americanbankingnews.comQuidelOrtho (NASDAQ:QDEL) Reaches New 52-Week Low on Analyst DowngradeApril 23 at 1:38 AM | marketbeat.comQuidelOrtho (NASDAQ:QDEL) Reaches New 52-Week Low Following Analyst DowngradeApril 23 at 1:29 AM | americanbankingnews.comQuidelOrtho Co. (NASDAQ:QDEL) Shares Sold by Russell Investments Group Ltd.April 22 at 3:19 AM | marketbeat.comJump Financial LLC Purchases New Shares in QuidelOrtho Co. (NASDAQ:QDEL)April 20, 2025 | marketbeat.comCerity Partners LLC Acquires 14,898 Shares of QuidelOrtho Co. (NASDAQ:QDEL)April 20, 2025 | marketbeat.comJ.P. Morgan Keeps Their Sell Rating on QuidelOrtho (QDEL)April 19, 2025 | markets.businessinsider.comQuidelOrtho (NASDAQ:QDEL) Sets New 1-Year Low - Here's WhyApril 18, 2025 | marketbeat.comGeode Capital Management LLC Increases Position in QuidelOrtho Co. (NASDAQ:QDEL)April 16, 2025 | marketbeat.comInvesco Ltd. Has $153.58 Million Holdings in QuidelOrtho Co. (NASDAQ:QDEL)April 15, 2025 | marketbeat.comNeuberger Berman Group LLC Has $12.98 Million Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL)April 13, 2025 | marketbeat.comQuidelOrtho (NASDAQ:QDEL) Reaches New 1-Year Low - Time to Sell?April 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCDX, LNTH, QDEL, and CLDX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$19.57 -0.01 (-0.05%) Closing price 04:00 PM EasternExtended Trading$19.58 +0.01 (+0.05%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Lantheus NASDAQ:LNTH$101.77 -1.87 (-1.80%) Closing price 04:00 PM EasternExtended Trading$102.24 +0.48 (+0.47%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Ortho Clinical Diagnostics NASDAQ:OCDXOrtho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.QuidelOrtho NASDAQ:QDEL$28.09 +0.31 (+1.12%) Closing price 04:00 PM EasternExtended Trading$28.11 +0.02 (+0.07%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
